News & Updates

Show Multimedia Only

Possible allergic reaction should not delay COVID-19 vaccination

10 Nov 2021 by

People who had an allergic response to the first dose of COVID-19 vaccination or who believe they will have an allergy to vaccination should not let their worries delay getting vaccinated — as most of them can still be fully vaccinated safely, suggest studies presented at ACAAI 2021.

Possible allergic reaction should not delay COVID-19 vaccination

10 Nov 2021

Ruxolitinib cream improves repigmentation in patients with vitiligo

09 Nov 2021 by

The application of ruxolitinib cream led to significant improvements in facial and total body repigmentation among adolescents and adults with vitiligo, according to two phase III studies presented at EADV 2021.

Ruxolitinib cream improves repigmentation in patients with vitiligo

09 Nov 2021

Rituximab induces good remission rates in pemphigus vulgaris

07 Nov 2021

A single cycle of rituximab treatment for pemphigus vulgaris achieves >30 percent complete remission rate after 1 year, which improves with longer follow-up and additional cycles, a new study has found.

Rituximab induces good remission rates in pemphigus vulgaris

07 Nov 2021

Pembrolizumab extends RFS in stage II melanoma

01 Nov 2021 by

Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.

Pembrolizumab extends RFS in stage II melanoma

01 Nov 2021

$Tirabrutinib safe, effective for refractory pemphigus$

Tirabrutinib safe, effective for refractory pemphigus

30 Oct 2021

Tirabrutinib induces remission and lowers oral corticosteroid exposure among patients with refractory pemphigus, a recent study has found.

Tirabrutinib safe, effective for refractory pemphigus

30 Oct 2021

Novel JAK3 blocker: Potential to stave off balding?

22 Oct 2021 by

The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.

Novel JAK3 blocker: Potential to stave off balding?

22 Oct 2021

$Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus$

Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus

22 Oct 2021

B-cell signalling suppression with tirabrutinib appears to promote remission in patients with refractory pemphigus, as shown in a phase II trial. Furthermore, treatment has reduced oral corticosteroid exposure over time without any major safety concerns.

Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus

22 Oct 2021

Bimekizumab maintains skin clearance in patients with plaque psoriasis

22 Oct 2021 by

Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.

Bimekizumab maintains skin clearance in patients with plaque psoriasis

22 Oct 2021

Onychomycosis worsens quality of life, warrants effective treatments

21 Oct 2021

Onychomycosis has a substantial impact on the quality of life of patients and requires effective treatment, results of a systematic review have confirmed.

Onychomycosis worsens quality of life, warrants effective treatments

21 Oct 2021

Substandard reporting of endpoints mars dermatology trials

20 Oct 2021

In recent dermatology literature, the quality of primary endpoint reporting of randomized controlled trials (RCTs) remains below average, according to the results of a recent study.

Substandard reporting of endpoints mars dermatology trials

20 Oct 2021

News & Updates

Showing Dermatology articles

Showing

Specialty:

Possible allergic reaction should not delay COVID-19 vaccination

Possible allergic reaction should not delay COVID-19 vaccination

Ruxolitinib cream improves repigmentation in patients with vitiligo

Ruxolitinib cream improves repigmentation in patients with vitiligo

Rituximab induces good remission rates in pemphigus vulgaris

Rituximab induces good remission rates in pemphigus vulgaris

Pembrolizumab extends RFS in stage II melanoma

Pembrolizumab extends RFS in stage II melanoma

Tirabrutinib safe, effective for refractory pemphigus

Tirabrutinib safe, effective for refractory pemphigus

Novel JAK3 blocker: Potential to stave off balding?

Novel JAK3 blocker: Potential to stave off balding?

Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus

Oral Bruton’s tyrosine kinase inhibitor shows therapeutic potential in refractory pemphigus

Bimekizumab maintains skin clearance in patients with plaque psoriasis

Bimekizumab maintains skin clearance in patients with plaque psoriasis

Onychomycosis worsens quality of life, warrants effective treatments

Onychomycosis worsens quality of life, warrants effective treatments

Substandard reporting of endpoints mars dermatology trials

Substandard reporting of endpoints mars dermatology trials